The frenzied dealmaking for antibody-drug conjugates is far from more than.
In the previous 10 days, there’s been a slew of ADC offers. Genmab produced its initial-ever acquisition — of ProfoundBio, which is in the clinic with multiple ADCs. Merck produced a modest guess on a startup seeking to make the medication safer on the heels of a huge ADC deal in the tumble. Ipsen obtained an asset on the verge of getting into human scientific studies, and blue-chip traders doled out $158 million for an ADC startup on the brink of Period 3.